Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se?
about
Post-transplant lymphoproliferative disorders are not associated with IgG4 sclerosing disease.Therapeutic options in post-transplant lymphoproliferative disorders.Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease.Posttransplant malignancy.Strategies for minimizing immunosuppression in kidney transplantation.Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability.Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation.Matched-pair analysis: identification of factors with independent influence on the development of PTLD after kidney or liver transplantation.Aftercare for patients with transplanted organs.Azathioprine as an alternative treatment in primary hypophysitis.Posttransplant lymphoproliferative disease in liver transplant patients.Posttransplant lymphoproliferative disease following liver transplantation.Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms.Time trends in risk and risk determinants of non-Hodgkin lymphoma in solid organ transplant recipients.Treatment of severe non-infectious uveitis in high-risk conditions (Part I): pregnancy and malignancies, management and safety issues.Use of polyclonal/monoclonal antibody therapies in transplantation.Epstein-Barr virus infection in adult renal transplant recipients.Non-Hodgkin's lymphoma manifest as gingival hyperplasia in a renal transplant recipientLowered Immune Cell Function in Liver Recipients Recovered From Posttransplant Lymphoproliferative Disease Who Developed Graft Tolerance.Posttransplant lymphoproliferative disorders.Three different histological subtypes of Epstein-Barr virus-negative post-transplant lymphoproliferative disorder in a patient with hepatitis C infection.Immunosuppressive therapy for eye diseases: Effectiveness, safety, side effects and their prevention.Post-transplant lymphoproliferative disorder in an adolescent masquerading as a complicated primary EBV infection.Posttransplant lymphoproliferative disorder presenting as multiple cystic lesions in a renal transplant recipient.Posttransplant lymphoproliferative disorder complicating hematopoietic stem cell transplantation in a patient with dyskeratosis congenita.Impact of the posttransplant lymphoproliferative disorder subtype on survival.Posttransplant Lymphoproliferative Disorder in Adults Receiving Kidney Transplantation in British Columbia: A Retrospective Cohort Analysis.Risk factors associated with post–kidney transplant malignancies: an article from the Cancer-Kidney International Network.Identifying High Risk Groups and Quantifying Absolute Risk of Cancer After Kidney Transplantation: A Cohort Study of 15 183 Recipients
P2860
Q30303135-BA1EC169-E2C9-45A5-88E0-37AB84425088Q30455714-9BEC7113-9DBA-4901-A385-8F4782C51DD8Q33346685-FC76B386-A4C7-4F45-9B04-C7C8415E72F0Q34078707-E691D37E-7D48-4588-B121-FB3C088E018BQ35923812-89009ABF-32D7-45BA-AF4D-5DA3BB26E5AFQ35990853-02855D33-78FB-47EC-9642-6DFBB952A3DBQ36544988-17D8F99C-AEE5-4780-B78C-DFFFAAE25B97Q36732580-7AA8D48F-BC0D-4B07-A468-E7855C7FD5B8Q37145738-0D855DD8-F5C8-42BE-9341-E5A6BBC87A19Q37227156-64A936C7-575F-475E-9AB0-D9D1DFC7A8F5Q37784432-683A1386-5208-4536-9D8A-23CA8B1BFCF6Q37838795-2AAF92B4-0AFD-41B0-BE9D-D09EB31FEDD6Q37862042-22A6C0DC-E003-44F9-8DA7-FA36707529E1Q38061056-15CB5C86-FB84-48E4-9A4F-CEEA5A7D0AD8Q38437273-3419AED7-D434-4EC3-B719-E0693D86366DQ38464355-08DC9061-EBBC-47FB-8E2C-1FA3E159D736Q38769922-365D522D-D2EE-4A4B-896E-B8CB0DE3D850Q39194877-EC9DD9F4-3E15-45C2-A952-7D9EFA4B673BQ41870362-5C140A40-2A12-4BD3-826A-5433EDA82E6EQ42053532-7A4ADFCF-EF4A-4F27-A97F-CBEBF15483CCQ42137120-4044824B-07E2-47F7-B82D-87D06E1238D0Q42215751-7E95108E-4D8A-46B3-B276-188C04B4DC18Q42359937-05D7D5F5-031B-4B42-B0EB-B61CBE94EE09Q42582483-1EEA2D60-D266-4784-9168-D9D8052418D2Q44964154-D2693853-AC33-49A7-BDE6-DD3CC1792D2AQ46117700-165E7B33-6103-402D-9D95-082F43097FF3Q51734713-1510DAF8-CDFC-487D-AC40-1C3E2FA734DAQ52595061-5B9E33DD-F4C5-4BD1-B786-8D68CB5A0623Q55266341-24F5A895-DF48-41DA-8131-BBFF013A8ADFQ59167779-5712A774-7A0E-4A05-95A0-C02132B0CE1C
P2860
Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se?
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Is posttransplant lymphoprolif ...... by the transplantation per se?
@en
Is posttransplant lymphoproliferative disorder
@nl
type
label
Is posttransplant lymphoprolif ...... by the transplantation per se?
@en
Is posttransplant lymphoproliferative disorder
@nl
prefLabel
Is posttransplant lymphoprolif ...... by the transplantation per se?
@en
Is posttransplant lymphoproliferative disorder
@nl
P1433
P1476
Is posttransplant lymphoprolif ...... by the transplantation per se?
@en
P2093
Birkeland SA
P304
P356
10.1097/01.TP.0000085602.22498.CF
P577
2003-09-01T00:00:00Z